The combined administration of YAK540 and the proteasome inhibitor bortezomib shows potential as a promising strategy against leukemias, as it enhances the anticancer efficacy while minimizing the overall toxicity associated with HDAC inhibitors (179). This evidence concerns the gene HDAC9 and leukemia.